In 2014, two landmark clinical trials (ASCEND and INPULSIS) were published
demonstrating, for the first time, a treatment benefit for patients with idiopathic pulmonary …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

In retrospect, 2014 will be seen as the year in which idiopathic pulmonary fibrosis (IPF)
therapies came of age. Treatment effects reported previously were inconclusive with regard …

Over the past two and a half decades, many clinical trials have been designed to determine
the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major
breakthrough in treatment came when, after decades of clinical trials which failed to identify …

Abstract Purpose of Review The approval of nintedanib and pirfenidone has changed the
treatment landscape of idiopathic pulmonary fibrosis (IPF); however, both drugs only slow …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing
incidence; the median survival is only 35 months and as yet no therapy has been proven to …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has
been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND …

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective
treatment and a median survival time of 2–5 yrs. The search for effective treatment has …

Despite the recent success of the nintedanib and pirfenidone programmes [1, 2], idiopathic
pulmonary fibrosis (IPF) remains a high-risk disease area for drug development. There are …